Nandi Ashim, Asadi Mojgan, Zhang Aoxuan, Chu Zhen T, Warshel Arieh
Department of Chemistry, University of Southern California, Los Angeles, California 90089-1062, United States.
Department of Chemistry, Stanford University, Stanford, California 94305-5012, United States.
ACS Catal. 2025 Jan 17;15(2):1158-1169. doi: 10.1021/acscatal.4c06020. Epub 2025 Jan 5.
The treatment of SARS-CoV-2 can be accomplished by effective suppression of its 3CL protease (3CL), also known as the main protease (M) and nonstructural protein 5 (nsp5). Covalent inhibitors can irreversibly and selectively disable the protease, particularly when they are highly exothermic. Herein we investigated the distinct kinetic behaviors exhibited by two covalently linked SARS-CoV-2 inhibitors. One of these inhibitors features a nitrile reactive group, while the other has this group replaced by an alkyne group, a less reactive electrophile. Our investigations involve the assessment of the free energy surfaces of the key feasible mechanisms: that is, direct and water-assisted mechanisms involved in the rate-determining proton-transfer nucleophilic attack step through the utilization of both ab initio and empirical valence bond (EVB) simulations. The calculated free energy profiles show that substituting the nitrile group with alkyne increases the chemical barrier but leads to very exothermic reaction energy and is an irreversible process as opposed to nitrile, which is moderately exothermic and reversible. We also examine the time dependence of IC50 inhibition by applying an innovative kinetic simulation approach, which is particularly important in studies of covalent inhibitors with a very exothermic bonding step. Our computational approach provides a good agreement between the calculated and observed values of the time dependence results for the nitrile and alkyne inhibitors. Our approach, which is rather unique in combining calculations of the chemical barriers and the binding energy is likely to be very effective in studies of the effectiveness of other covalent inhibitors related cases.
严重急性呼吸综合征冠状病毒2(SARS-CoV-2)的治疗可通过有效抑制其3C样蛋白酶(3CL)来实现,该蛋白酶也被称为主要蛋白酶(M)和非结构蛋白5(nsp5)。共价抑制剂可以不可逆地、选择性地使该蛋白酶失活,尤其是当它们具有高放热性时。在此,我们研究了两种共价连接的SARS-CoV-2抑制剂所表现出的不同动力学行为。其中一种抑制剂具有腈反应基团,而另一种则将该基团替换为炔基,炔基是一种反应性较低的亲电试剂。我们的研究涉及对关键可行机制的自由能面进行评估:即通过利用从头算和经验价键(EVB)模拟,在速率决定质子转移亲核攻击步骤中涉及的直接和水辅助机制。计算得到的自由能剖面图表明,用炔基取代腈基会增加化学势垒,但会导致非常放热的反应能量,并且是一个不可逆过程,而腈基则是中等放热且可逆的。我们还通过应用一种创新的动力学模拟方法来研究IC50抑制的时间依赖性,这在研究具有非常放热键合步骤的共价抑制剂时尤为重要。我们的计算方法在腈基和炔基抑制剂的时间依赖性结果的计算值和观测值之间提供了良好的一致性。我们的方法在结合化学势垒和结合能计算方面相当独特,可能在研究其他共价抑制剂相关情况的有效性方面非常有效。